Stockwinners Market Radar for November 06, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:45 EST Tappy Technologies, MasterCard to partner on payment technology platform in Asia - Tappy Technologies, the Hong Kong-based wearable and digital payments solution provider, announces a strategic partnership with Mastercard in the Asia Pacific region. The patented technology of Tappy embeds contactless payment chips into any accessory, transforming them into payment-enabled wearables. By partnering with Mastercard, Tappy can integrate its technology platform with Mastercard Digital Enablement Service tokenization platform for tokenizing payment credentials across mechanical and digital watches for use across contactless payments accepting Mastercard merchants.

19:31 EST Hamilton Beach board approves $25M stock repurchase program - Hamilton Beach board approved a stock repurchase program providing for the purchase of up to $25 million of the company's outstanding common stock starting January 1, 2020 and running through December 31, 2021.

19:01 EST LGI Homes expands presence in Dallas-Fort Worth - LGI Homes announced an expansion within the Dallas-Fort Worth market with the opening of two communities in the month of November, Eagle Lake Garden Village and Lake Ridge Estates, as well as the opening of a new section at the popular community Patriot Estates. Eagle Lake Garden Village, located just north of Fort Worth in Azle, is ideally situated just a short commute to all of the exciting attractions that downtown Fort Worth has to offer. Close to home, residents will enjoy local outdoor attractions such as Ash Creek Park, Shady Grove Park and Eagle Mountain Lake. LGI Homes will construct 30 homes within the community which will range in size from 1,236 square feet to just over 2,000 square feet, all featuring the CompleteHome interior package. Granite countertops, designer wood cabinetry, Whirlpool(R) kitchen appliances and more add style, energy-efficiency and value to every home. Three- and four-bedroom homes will be available for quick move-in at Eagle Lake Garden Village with pricing starting from the $190s. Ideally located just north of Denton, in Sanger, Texas is the brand-new community of Lake Ridge Estates. This highly desirable neighborhood boasts a stocked fishing pond, a children's playground and walking paths. Within the neighborhood, LGI Homes will construct five floor plans ranging in size from 1,401 square feet to 2,625 square feet with up to five bedrooms and two and a half baths. Each LGI home constructed in this community includes a stately brick exterior, professional front yard landscaping, a fully fenced backyard and comes equipped with LGI Homes' CompleteHome interior package. Prices at Lake Ridge Estates will start in the $210s. To introduce this new community, LGI Homes will host a grand opening event at Lake Ridge Estates on November 16, 2019.

18:27 EDT GoDaddy up 10% to $69.26 after Q3 profit tops estimates

18:19 EDT Alliant Energy increases 2020 expected annual dividend target 7% to $1.52 - Alliant Energy's Board of Directors approved a 7% increase, or 10c per share, to its 2020 expected annual common stock dividend target of $1.52 per share from the current annual common stock dividend target of $1.42 per share. Payment of the 2020 quarterly dividend is subject to the actual dividend declaration by the Board of Directors each quarter, which is expected in January 2020 for the Q1 dividend.

18:05 EDT GeoPark reports Q3 consolidated oil/gas production up 6% at 39.6K boe/d

17:55 EDT Rent-A-Center reports Q3 SSS up 4.5% - CEO Mitch Fadel says: "I'm pleased to report strong third quarter results, which met our expectations. Consolidated same store sales increased 4.5% and the continued execution of our strategic plan drove adjusted EBITDA growth of 14.8% versus the third quarter of last year. As a result we are reiterating and narrowing our annual guidance. The integration with Merchants Preferred is progressing ahead of our expectations and we continue to believe our differentiated platform of offering both staffed and virtual options for our retail partners positions us for significant growth, including growth in national accounts and e-commerce retailers. Our focus is to serve lease-to-own customers across multiple channels by enhancing the customer experience through enabling technologies. In addition, we maintain a conservative balance sheet with ample capital to fund our growth initiatives and return capital to shareholders."

17:50 EDT Rosetta Stone down 6.5% after reporting Q3 results, giving FY19, FY20 guidance

17:44 EDT Sodexo awarded $117.78M Navy contract modification for mess hall management - Sodexo awarded a $117.78M firm-fixed-price modification under a previously awarded contract for the management and operation of mess halls in support of the Marine Corps Regional Garrison Food Services Program. FY20 military personnel funding for $19.74M will be obligated at the time of award and will expire at the end of the current fiscal year. Marine Corps Installation Command is the contracting activity.

17:34 EDT Select Energy Services lowers 2019 CapEx view to $100M-$110M from $120M-$140M

17:30 EDT Talos Energy sees FY19 CapEx $540M-$550M

17:25 EDT Protagonist Therapeutics says first patient dosed in Phase 2 study of PTG-200 - Protagonist Therapeutics announced that the first patient has been dosed in a Phase 2 study of PTG-200 in patients with moderate to severe Crohn's disease. PTG-200 is an oral, gut-restricted, interleukin-23 receptor antagonist for the potential treatment of inflammatory bowel diseases. Protagonist Therapeutics and Janssen Research & Development are jointly conducting the development of PTG-200 through completion of Phase 2 clinical proof of concept in the treatment of Crohn's disease.

17:24 EDT MDU Resources subsidiary receives permit for Texas quarry operations - Knife River Corporation, the construction materials subsidiary of MDU Resources Group, announced it has received permitting to begin operations at a strategic new aggregate quarry in Texas. The quarry contains an estimated 40-year supply of high-quality aggregates, enabling Knife River to self-supply a significant portion of the base materials it uses for construction and for the production of ready-mix concrete and asphalt. The site also will be open to third-party sales. The 570-acre property, known as the Honey Creek Quarry, is northwest of Austin in Burnet County, Texas. The Texas Commission on Environmental Quality has granted Knife River an Air Quality Standard Permit to construct a rock-crushing plant at the quarry. Knife River anticipates production at the site will begin in the third quarter of 2020.

17:21 EDT Information Services authorizes share repurchase expansion to up to $20M - Information Services approved a new share repurchase authorization of $10.8M, increasing to $20M the aggregate available under its share repurchase program. The new share repurchase program will take effect upon completion of the company's current program, which has approximately $9.2M remaining.

17:21 EDT Carvana down 5% after reporting Q3 results, raising FY19 revenue guidance

17:12 EDT FGL Holdings names John Fleurant as CFO, succeeding Dennis Vigneau - FGL Holdings announced the appointment of John Fleurant as CFO, effective November 11, following a comprehensive search process. Fleurant succeeds Dennis Vigneau, who previously announced his intention to retire at the end of 2019. Fleurant brings more than three decades of finance experience, most recently having spent nearly 10 years at New York Life, including as Executive Vice President and CFO since 2013.

17:06 EDT OMA reports October terminal passenger traffic up 8.3% - Grupo Aeroportuario del Centro, known as OMA, reported that terminal passenger traffic at its 13 airports increased 8.3% in October 2019, as compared to October 2018. Domestic traffic increased 8.2%, and international traffic increased 9.6%.

17:02 EDT eGain backs FY20 SaaS revenue view $53.8M-$55.4M

16:59 EDT Bristol-Myers' Schmukler sells 25,000 common shares - In a regulatory filing, Bristol-Myers president of global manufacturing and supply Louis S. Schmukler disclosed the sale of 25,000 common shares of the company at a price of $56.56 per share.

16:55 EDT HP Inc. confirms receiving proposal from Xerox - HP Inc. (HPQ) issued the following statement: "As reviewed at HP's most recent Securities Analyst Meeting, we have great confidence in our multi-year strategy and our ability to position the company for continued success in an evolving industry, particularly given the multiple levers available to drive value creation. Against this backdrop, we have had conversations with Xerox Holdings Corporation (XRX) from time to time about a potential business combination. We have considered, among other things, what would be required to merit a transaction. Most recently, we received a proposal transmitted yesterday. We have a record of taking action if there is a better path forward and will continue to act with deliberation, discipline and an eye towards what is in the best interest of all our shareholders."

16:51 EDT Roan Resources to temporarily curtail drilling, development activity - Roan has also elected to temporarily curtail its drilling and development activity and to suspend all completion activity. This reduction in activity is to allow our new CEO, Rick Gideon, time to assess the Company's overall operations plan. As a result of this change, investors should no longer rely on the guidance provided by the Company on its last quarterly investor call, and Roan does not expect to otherwise update or provide further guidance.

16:45 EDT InflaRx NV trading resumes

16:37 EDT Eldorado Resorts CEO says 'increasingly excited' about Caesars acquisition - CEO Tom Reeg says: "As we continue to move through the regulatory review process in advance of the expected closing in the first half of 2020 for the Caesars Entertainment acquisition, our senior management and integration team has now had the opportunity to visit every domestic Caesars asset. We are increasingly excited about the opportunity to combine best practices from each company. We remain confident that the national, multi-brand footprint across all major and regional markets created by the combination of Eldorado and Caesars is a strategically, financially and operationally compelling opportunity that is expected to deliver value to shareholders and stakeholders of both companies."

16:35 EDT Natural Gas Services CFO G. Larry Lawrence to retire - Natural Gas Services Group announced that G. Larry Lawrence, the company's VP, CFO and Corporate Secretary will retire from the company effective November 15. He will also relinquish his position as Principal Accounting Officer. Coincident with the retirement of Larry Lawrence, the board has appointed James Lawrence as VP, CFO and Corporate Secretary, effective November 16. Lawrence will also assume the role as Principal Accounting Officer. Lawrence joined the company on October 1. Previously, he served as the CFO of Bold Energy III LLC.

16:35 EDT Columbus McKinnon plans closure of Ohio operation - Columbus McKinnon announced that it will be closing its Lisbon, Ohio factory and consolidating this operation into its facilities in Virginia and North Carolina. Mark Morelli, President and Chief Executive Officer commented, "We are continuously identifying opportunities to simplify our business. This consolidation will provide better service and an improved overall experience for our customers, while driving value. Over the last year, we have transformed the Wadesboro, North Carolina and Damascus, Virginia facilities into "assembly-manufacturing centers of excellence" for wire rope and electric chain hoists, respectively. With the closure of the Lisbon, Ohio operation, we will transfer more product lines into these Centers of Excellence." The Lisbon, Ohio facility was part of the Chester Hoist acquisition in 1995. The closure of the Lisbon operation will affect 59 union associates and 17 staff associates in that location. The restructuring process is expected to take between seven to ten months. The Company expects plant closure costs of approximately $3.5 million and estimates annual savings of $5.0 million once completed.

16:32 EDT Atmos Energy raises quarterly dividend to 57.5c per share - Atmos Energy Corporation said that its Board of Directors declared a quarterly dividend increase on the company's common stock to $0.575 cents per share. The Fiscal 2020 indicated annual dividend is $2.30. The Fiscal 2019 annual dividend was $2.10.

16:28 EDT Hawaiian Airlines reports October traffic up 5%, capacity up 2.1% - Load factor of 88% was up 2.4 pts.

16:24 EDT Ardelyx still sees cash and cash equivalents sufficient until early 2021

16:19 EDT AXA Equitable announces $400M share repurchase authorization - AXA Equitable Holdings, Inc. announced that its Board of Directors has authorized a new $400 million share repurchase program. "This authorization accelerates our 2020 capital management program and supports our commitment to return 50-60% of Non-GAAP Operating Earnings to shareholders on an annualized basis," said Mark Pearson, President and CEO of AXA Equitable Holdings. "Since our IPO in May of 2018, AXA Equitable Holdings has returned $1.8 billion to shareholders in the form of quarterly dividends and share repurchases. We believe that this authorization further demonstrates the Board's confidence in the strength and stability of our balance sheet and our ability to deliver sustainable cash flows and generate long-term shareholder value."

16:16 EDT National Bank increases quarterly dividend 5.3% - National Bank Holdings Corporation announced that its board approved a cash dividend to shareholders. The quarterly cash dividend will increase 5.3% to 20c per share from 19c per share of common stock. The dividend will be payable on December 13 to shareholders of record at the close of business on November 29.

16:15 EDT Quotient Technology acquires Ubimo, terms not stated - Quotient Technology announced that it has agreed to acquire Israel-based Ubimo, a data and media activation company. Through its demand-side platform, Ubimo will bring "best in-class" technology to further strengthen Quotient's targeted digital media solutions, accelerate the development of Quotient's self-service platform, and meet the needs of consumer-packaged goods brands and retailers.

16:09 EDT Fox Corp. announces $2B stock repurchase program - Fox Corporation announced that its Board of Directors has authorized a $2B stock repurchase program. Subject to market conditions and other factors, the company intends to repurchase, in the open market or otherwise, a combination of the company's Class A common stock and Class B common stock. This stock repurchase program has no time limit and may be modified, suspended or discontinued at any time. The company also announced that it has entered into an accelerated stock repurchase transaction to repurchase, in the aggregate, $350M of the company's Class A common stock pursuant to the stock repurchase program. The company also intends to promptly repurchase approximately $150M of Class B common stock. As a result, the company expects to complete approximately $500M of aggregate stock repurchases in the near term. The Board's decision follows the execution of a stockholders agreement by and between the company and the Murdoch Family Trust, which was approved by the independent members of the Board, and which limits the potential accretion of voting power by the MFT and Murdoch family members through market purchases or as an indirect result of repurchases by the Company of shares of Class B common stock. Lachlan Murdoch, Executive Chairman and CEO, commented: "We are committed to deploying capital to maximize long-term stockholder value through a balanced approach of appropriate organic investment, accretive M&A, and returns of capital to our stockholders. This stock buyback program reflects the confidence we have in the long-term investment case for the Company, which is underpinned by the strength of our core brands and the sustainability of our business, and which we believe is well positioned to continue to generate healthy free cash flow."

16:07 EDT Qualcomm removes interim tag from CFO Akash Palkhiwala - Qualcomm announced that its board has unanimously approved the appointment of Akash Palkhiwala as executive vice president and Chief Financial Officer. Palkhiwala has been serving the company as interim CFO since August.

16:06 EDT Wynn says on track to launch renovated West Casino at Wynn Macau in late 2019 - Matt Maddox, CEO of Wynn Resorts, said, "On the development front, we are on track to launch the renovated West Casino at Wynn Macau beginning in late 2019, further solidifying the property as the peninsula's marquee integrated resort. In Las Vegas, our 430,000 square foot group space expansion is on schedule to open in the first quarter of 2020 and feedback from meeting planners has been very encouraging."

16:04 EDT Carrizo Oil & Gas shareholder votes against acquisition by Callon Petroleum - Callon Petroleum (CPE) shareholder Paulson & Co, as manager of funds holding 21.6 million shares, or 9.5% of those outstanding, of Callon, voted its Callon shares against the proposed acquisition of Carrizo Oil & Gas (CRZO). Paulson notes that ISS and Glass Lewis both recommend that Callon shareholders vote against the company's proposed acquisition of Carrizo. Paulson & Co. stated that "If, on November 14th, Callon shareholders reject the approval of the proposed acquisition, Paulson requests that the Callon Board should follow the will of its shareholders and direct management to focus on: reducing G&A costs, which have risen by over $12M for the first nine months of 2019 versus 2018; focusing its SIMOPS mega-pad development on its extensive stand-alone acreage; delivering on generating true corporate-level free cash flow organically starting in the fourth quarter of this year assuming $50/bbl, as previously guided (page 14 of its February 26, 2019 presentation); and engaging new, independent advisors to pursue a sale of Callon".

16:03 EDT Coherus Biosciences acquires commercial rights for Lucentis biosimilar - Coherus BioSciences announced the company has acquired exclusive rights from Bioeq IP AG, a Swiss biopharmaceutical joint venture, to commercialize Bioeq's biosimilar candidate to Lucentis in the United States. Bioeq plans to file a Biologics License Application with the FDA in Q4 and Coherus plans to launch the product in 2021. According to the terms of the agreement, Coherus will make a mid-single digit million-dollar upfront payment as well as other regulatory and launch milestone payments. The companies will share profits approximately equally.

15:58 EDT Voce Capital says 'abrupt CEO transition does not allay concerns' about Argo - Voce Capital Management, the beneficial owner of approximately 5.8% of the shares of Argo Group International Holdings, issued a statement commenting on Argo's recent CEO transition announcement: "The abrupt 'retirement' of Argo's CEO yesterday does not resolve our concerns about the Company's operations, strategy and corporate governance; in fact, it raises more questions than it answers. As we stated in our October 14 press release following the initial news of the SEC probe, '[t]he disclosure that the Company is now under federal investigation vividly illustrates the need for immediate and sweeping changes at Argo. . . . [We] do not believe that a Board that allowed myriad corporate governance transgressions at Argo can be trusted to deliver the Company from the resulting crisis which now engulfs it.'"

15:08 EDT BeiGene treatment of esophageal cancer granted orphan designation - BeiGene's tislelizumab was granted orphan designation by the FDA as a treatment of esophageal cancer, according to a post to the agency's website. Reference Link

14:11 EDT California AG petitions court to force Facebook to comply with subpoena - California Attorney General Xavier Becerra filed a petition in the San Francisco Superior Court requesting that the court order Facebook to comply with an outstanding subpoena and investigative interrogatories issued by the Attorney General on behalf of the People of California on June 17, 2019. The state's petition alleges that Facebook has failed to comply with the Attorney General's subpoena and interrogatories by providing inadequate responses and failing to provide, or even search for, responsive documents among the communications of the company's senior executives. "The California Department of Justice, pursuant to its statutory authority, issued investigative subpoenas against Facebook starting back in June 2018 to examine the company's actions and business practices and any violations of user privacy. The responses we have received to date are patently inadequate. Our work must move forward. We are left with little choice but to seek a court order compelling Facebook to faithfully comply with our duly authorized subpoenas," said Attorney General Becerra. Reference Link

14:03 EDT Cinedigm acquires holiday film '2nd Chance for Christmas' - Cinedigm announced the acquisition of Cinetel Films' holiday film "2nd Chance for Christmas" starring Brittany Underwood, Vivica A. Fox, and Tara Reid. Cinedigm will distribute the film in the U.S. and Canada that is scheduled to release on Digital on November 19 followed by the DVD release on December 3.

13:29 EDT Oil majors fall after EIA report shows crude inventory build - The EIA summary of weekly petroleum data for the week ending November 1 sent crude oil prices lower on Wednesday. U.S. crude oil refinery inputs averaged 15.8M n barrels per day during the week ending November 1, which was 237,000 barrels per day less than the previous week's average. Refineries operated at 86.0% of their operable capacity last week. Gasoline production decreased last week, averaging 10M barrels per day. Distillate fuel production decreased last week, averaging 4.9M barrels per day. U.S. commercial crude oil inventories, excluding those in the Strategic Petroleum Reserve, increased by 7.9M barrels from the previous week. At 446.8M barrels, U.S. crude oil inventories are about 3% above the five year average for this time of year. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT).

13:23 EDT Devon Energy, QLCP partner to fund Delaware Basin gas gathering infrastructure - QL Capital Partners and Devon Energy Corporation have entered into an agreement to create a new partnership to fund selected gas gathering and compression assets owned by Devon in the company's "Cotton Draw" development area within the Delaware Basin. As part of the transaction, Devon will contribute its existing gas gathering and compression infrastructure within an area of mutual interest to Cotton Draw Midstream, a newly formed partnership which Devon will continue to operate pursuant to a management services agreement. Devon will dedicate to the Partnership approximately 24,000 gross upstream acres for gathering and compression on the Partnership's system. Per the terms of the agreements, QLCP will fund a $100 MM distribution to Devon, and will also fund the majority of incremental Partnership capital to build out the Cotton Draw midstream assets over the next several years. Kirkland & Ellis served as legal counsel to QLCP and Vinson & Elkins served as legal counsel to Devon.

13:05 EDT Nvidia posts 'fastest results' on new AI inference benchmarks - NVIDIA posted the fastest results on new benchmarks measuring the performance of AI inference workloads in data centers and at the edge - building on the company's equally strong position in recent benchmarks measuring AI training. The results of the industry's first independent suite of AI benchmarks for inference, called MLPerf Inference 0.5, demonstrate the performance of NVIDIA Turing GPUs for data centers and NVIDIA Xavier system-on-a-chip for edge computing.MLPerf's five inference benchmarks - applied across a range of form factors and four inferencing scenarios - cover such established AI applications as image classification, object detection and translation. NVIDIA topped all five benchmarks for both data center-focused scenarios, with Turing GPUs providing the highest performance per processor among commercially available entries1. Xavier provided the highest performance among commercially available edge and mobile SoCs under both edge-focused scenarios. "AI is at a tipping point as it moves swiftly from research to large-scale deployment for real applications," said Ian Buck, general manager and vice president of Accelerated Computing at NVIDIA. "AI inference is a tremendous computational challenge. Combining the industry's most advanced programmable accelerator, the CUDA-X suite of AI algorithms and our deep expertise in AI computing, NVIDIA can help data centers deploy their large and growing body of complex AI models."

12:49 EDT Bloomin' Brands jumps as company explores strategic alternatives - Shares of Bloomin' Brands (BLMN) were trading sharply higher after the restaurant operator reported quarterly results and announced that it is exploring strategic alternatives. EARNINGS/GUIDANCE: Before the market open, Bloomin' Brands reported third quarter adjusted earnings per share of 10c on revenue of $967.1M, compared to consensus estimates of 10c and $965.7M, respectively. Comparable restaurant sales rose 0.2% at U.S. Outback Steakhouse and increased 11.2% for Outback Steakhouse in Brazil, the company said. Looking ahead, Bloomin' Brands reiterated its fiscal 2019 adjusted EPS view of $1.53-$1.61 and lowered its FY19 combined U.S. same-store sales guidance to roughly 1.5% from 2%-2.5%. Analysts expect the company to report FY19 EPS of $1.55. STRATEGIC ALTERNATIVES: Along with its report, Bloomin' Brands announced that it is exploring and evaluating strategic alternatives that "have the potential to maximize value for our shareholders, including but not limited to, a possible sale of the company." The company noted that its board of directors has retained BofA Securities as its financial advisor. "Over the past few years Bloomin' Brands has made significant progress towards its long term objectives to elevate the customer experience, capitalize on the emerging off-premises segment, expand the rapidly growing international business, and improve operating margins. These efforts have created significant market share gains and enhanced profitability," said David Deno, chief executive officer of Bloomin' Brands. "However, despite this continued progress, we believe the current stock price does not reflect the value of the company. That is why the time is right to explore strategic alternatives that have the potential to maximize value for our shareholders. Our Board of Directors is committed to fully evaluating appropriate strategic alternatives while simultaneously supporting the company's ongoing progress against our business plan." Bloomin' Brands added that it intends to proceed in a timely manner, but has not set a definitive timetable for completion of this process. WHAT'S NOTABLE: On August 30, Barry Rosenstein's Jana Partners disclosed a 9% stake in Bloomin' Brands, saying in a regulatory filing at the time that Jana intended to have discussions with the company's board of directors and management regarding a sale of the company, divestitures, capital allocation, operations and board composition. PRICE ACTION: In afternoon trading, Bloomin' Brands shares are 9.6% higher at $22.95.

12:11 EDT Cars.com's Q3 revenue beats estimates, FY19 guidance is maintained - Shares of Cars.com (CARS) moved higher in early afternoon trading after the company's revenue for the third quarter beat analysts' expectations and the company backed its guidance for fiscal 2019. Cars.com also said average monthly unique users were up 22% year-over-year. EARNINGS: On Wednesday before the market open, Cars.com reported Q3 adjusted earnings per share of 32c, compared to analysts' consensus estimates of 36c and the 55c per share it reported in the prior year. Revenue for the quarter of $152.1M exceeded the $149.91M consensus, but declined 10% year-over-year. A non-cash goodwill and intangible asset impairment charge of $431.3M, net of tax, triggered by a decline in share price following the completion of the strategic alternatives review, resulted in net loss of ($426.2M), or ($6.38) per share, the company said in a statement. Cars.com said average monthly unique users were 23.1M, an increase of 22% year-over-year, while traffic was up 27% year-over-year to 144.4M. GUIDANCE: "With the affiliate conversions complete, our traffic and solutions strategy ramping, the tech transformation progressing on schedule, and our continued focus on operational efficiencies, we remain on track to deliver our 2019 outlook," said Cars.com CEO Alex Vetter. The company still sees FY19 revenue declining between 6% and 9%, with adjusted EBITDA margin between 27% and 29%. Analysts currently expect the company's FY19 revenue to be $605.61M. EXECUTIVE APPOINTMENT: Cars.com said that it has appointed Dean Evans as executive VP. Evans has over 20 years of experience at major automotive brands with a focus on sales, and the company noted he served four years as CMO of Hyundai Motor America and three years as CMO of Subaru of America prior to joining Cars.com. ANALYST COMMENTARY: Following the earnings report, Barrington analyst Gary Prestopino upgraded Cars.com to Outperform from Market Perform with a $20 price target. Key Performance Indicators, including average monthly unique visitors, traffic visits, and mobile traffic, showed significant year-over-year improvement and pointed to continued market share gains, noted Prestopino. PRICE ACTION: Just after noon, shares of Cars.com are up more than 1.2% to $11.99.

12:01 EDT BlueLinx falls -36.8% - BlueLinx is down -36.8%, or -$11.41 to $19.59.

12:00 EDT LendingClub rises 15.5% - LendingClub is up 15.5%, or $2.05 to $15.25.

12:00 EDT Venator Materials rises 24.9% - Venator Materials is up 24.9%, or 73c to $3.66.

11:40 EDT Constellation soars 110% after reporting new data from myelofibrosis trial - Constellation Pharmaceuticals announced earlier that abstracts with preliminary data from the Manifest clinical trial from 59 enrolled patients as of June 27, 2019, the data cutoff date, were published today in association with the Society of Hematology meeting. In Arm 3, which evaluates CPI-0610 for myelofibrosis in combination with ruxolitinib in a first-line setting in JAK-inhibitor-naive patients, all four evaluable patients experienced at least a 35% spleen volume reduction and at least a 50% reduction in total symptom score, which are the primary endpoints for these patients, the compamy said. In Arms 1 and 2, which are evaluating CPI-0610 in combination with ruxolitinib and as a monotherapy in a second-line setting in ruxolitinib-resistant or -intolerant patients, "additional preliminary data showed continuing signs of activity across a broad range of parameters, including spleen volume reduction, patient-reported symptom improvement, hemoglobin increases, conversion to transfusion independence in transfusion-dependent patients, and bone marrow fibrosis score improvement, consistent with preliminary data presented at ASCO and EHA in June," according to Constellation. The company noted that CPI-0610 was generally well-tolerated, both as a monotherapy or in combination with ruxolitinib. One ruxolitinib-resistant or -intolerant patient discontinued due to serious adverse event, which were reported as unlikely related to CPI-0610. No JAK-inhibitor-naive patients discontinued due to adverse events.

11:34 EDT Antengene announces exclusive worldwide license from AstraZeneca for AZD0364 - Antengene Corporation, a China-and-U.S. based clinical-stage biopharmaceutical company focused on discovery and development of novel drugs for treatment of oncology, announced that it has entered into a licensing agreement with AstraZeneca, under which Antengene has been granted the exclusive global rights to further develop and commercialize AZD0364. AZD0364 is a potent and selective small molecule extracellular signal-regulated kinases 1 and 2 inhibitor with an open U.S. investigational new drug application. Any existing agreement regarding the licensing of AZD0364 has been nullified in advance of this agreement between Antengene and AstraZeneca. Jay Mei, Founder and CEO of Antengene, said, "We are delighted to have the opportunity to work with AstraZeneca. ERK/RAS/MAPK is a key pathway excessively activated in cancers. AZD0364 is a strategic fit to our pipeline and pre-clinical studies demonstrated promising synergistic effects of AZD0364 in combination with other pipeline assets of Antengene targeting critical pathways in cancer treatment. We look forward to a close collaboration with AstraZeneca to bring more novel therapies to patients with unmet medical needs."

10:40 EDT PG&E trading resumes

10:35 EDT PG&E trading halted, volatility trading pause

10:10 EDT Acceleron sees pulmonary, neuromuscular disease data in Q1 of 2020 - The company said, "While our hematology program continues to grow, we are also advancing our two Acceleron-led clinical programs in pulmonary and neuromuscular disease. We anticipate reporting results in the first quarter of 2020 for both our PULSAR Phase 2 sotatercept trial in patients with PAH, and our ACE-083 trial in patients with CMT."

10:04 EDT Arcos Dorados furthers transition to serving cage free eggs in Brazil - Arcos Dorados (ARCO) announces that has begun purchasing eggs from cage-free hens in Brazil. This is further affirmation of the brand's global commitment to animal welfare while positioning the Brazilian market as Latin America's bellwether in achieving the Company's goal to fully transition to cage-free eggs by 2025, aligned with the McDonald's (MCD) system's 2030 global goals of minimizing the environmental impact of restaurant operations and building a more sustainable supply chain. The initial phase of this transition focuses on the Company's Parana distribution center which supplies the Chain's southern Brazil restaurants. The plan is a subsequent phased extension of supply throughout Brazil and the rest of the countries served by Arcos Dorados.

09:47 EDT Nu Skin falls -14.2% - Nu Skin is down -14.2%, or -$6.59 to $39.76.

09:47 EDT Poly falls -30.5% - Poly is down -30.5%, or -$12.01 to $27.43.

09:47 EDT Aircastle rises 16.3% - Aircastle is up 16.3%, or $4.51 to $32.10.

09:45 EDT Constellation Pharmaceuticals Inc trading halted, volatility trading pause

09:33 EDT Sellas Life Sciences announces 1-for-50 reverse stock split - SELLAS Life Sciences Group announced that it filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of its common stock. The shares underlying the Company's outstanding options and warrants will also be adjusted accordingly. The reverse split will take effect at 5:00 pm Eastern Time on November 7, 2019 and the Company's common stock will open for trading on The Nasdaq Capital Market on November 8, 2019 on a post-split basis. At the Company's Special Meeting of Stockholders held on September 10, 2019, SELLAS' stockholders approved a reverse stock split within a range of 1-for 20 and 1-for-60. The specific ratio of 1-for-50 was approved by the Company's Board of Directors. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. As a result of the reverse stock split, every 50 shares of the Company's common stock issued and outstanding prior to the opening of trading on November 8, 2019 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.0001. No fractional shares are being issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu thereof. Trading of the Company's common stock on The Nasdaq Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Friday, November 8, 2019, under the existing ticker symbol "SLS" but with a new CUSIP number 81642T 209. The reverse stock split reduces the number of shares of the Company's common stock outstanding from approximately 228 million pre-reverse split shares to approximately 4.6 million post-reverse split shares. The Company has retained its transfer agent, Computershare Trust Company, N.A., to act as its exchange agent for the reverse split. Computershare will provide stockholders and warrant holders of record as of the effective date of the reverse stock split instructions for the exchange of their certificates and/or warrants. Stockholders owning shares and/or warrants via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.

09:27 EDT Moxian signs letter of intent with Beijing Bi Er Culture Communication - Moxian announced the signing of a Letter of Intent with Beijing Bi Er Culture Communication Co. Ltd., pursuant to which, Moxian may, upon a satisfactory completion of due diligence and an audit of past financial statements, enter into a definitive agreement to acquire a controlling stake of Bi Er, the terms of which have yet to be finalised and which will be subject to approval by the shareholders of the Company in a general meeting. Bi Er is a limited company incorporated under the laws of the Peoples' Republic of China in June 2013 and is involved in the industry of mobile gaming, e-sports, animation and comics. It has successfully organized many e-sports competitions in various cities in China with strong support from the local governments and is generally regarded as a leading player in the e-sports industry in the country.

09:26 EDT Aircastle raises quarterly dividend 6.7% to 32c from 30c per share - Payable on December 13 to shareholders of record on November 29.

09:23 EDT Orchard Therapeutics to present registrational data on gene therapies - Orchard Therapeutics announced the upcoming presentation of registrational data from multiple programs at the 61st American Society of Hematology Annual Meeting in Orlando, FL. Investigators will describe ongoing clinical progress for two lead development programs in the company's primary immune deficiencies portfolio: OTL-103, an investigational gene therapy in development for the treatment of Wiskott-Aldrich syndrome at the San Raffaele-Telethon Institute for Gene Therapy in Milan, Italy; and OTL-101, an investigational gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency. In addition, investigators will deliver an oral presentation featuring updated data from the ongoing proof-of-concept study of OTL-203, an investigational gene therapy in development for the treatment of mucopolysaccharidosis type I at SR-Tiget. Lentiviral Hematopoietic Stem and Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome: This presentation includes results from an integrated analysis of 17 patients treated with OTL-103 for the treatment of WAS, including the complete data set for the eight patients from the registrational study and nine who received OTL-103 as part of an expanded access program. Participants have been followed for a median of three years. In the eight-patient registrational trial, investigators reported that the study achieved its key primary and secondary endpoints at three years, including the elimination of severe bleeding episodes and a significant reduction in the frequency of moderate bleeding episodes. Successful engraftment was observed within three months, leading to an increase in WAS protein expression and a vector copy number that has been maintained for up to eight years. Nine months post-administration, all patients stopped receiving platelet transfusions, and no severe bleeding events were reported. A significant reduction in the rate of severe infections was also observed and all patients were able to stop immunoglobin replacement therapy, suggesting a complete reconstitution of immune function with durability of effect of up to eight years of follow-up post-gene therapy. Similar clinical results were seen in the integrated analysis of 17 patients and overall survival was 94%. One death occurred among the EAP cohort that was considered by the investigator to be unrelated to OTL-103. Across the original and integrated data sets, there were no adverse events considered to be related to OTL-103, including no evidence of oncogenesis, replication competent lentivirus or abnormal clonal proliferation. Clinical benefit was also attained in patients older than five years of age, a group considered at higher risk when treated with allogeneic hematopoietic stem cell transplantation. Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency: This presentation details the safety and efficacy of OTL-101 in 30 individuals with ADA-SCID, treated with either fresh or cryopreserved formulations. Patients were followed for a median of 24 months, and results were compared with a historical cohort of 26 ADA-SCID patients treated with allogeneic hematopoietic stem cell transplantation, including HSCT both with, and without, a matched related donor. Results showed engraftment of genetically modified hematopoietic stem cells in 29 of 30 OTL-101 patients by six to eight months, which persisted through follow-up in both studies. Analysis of both the vector copy number in granulocytes and T-cell reconstitution showed consistent performance across the fresh and cryopreserved-treated patients. In the OTL-101 treated patients, overall survival was 30/30 and event-free survival was 29/30. One of the 30 patients restarted treatment with enzyme replacement therapy and subsequently withdrew from the study and received a rescue HSCT. In the historical control population, 42% of HSCT patients required re-initiation of ERT, rescue HSCT or other intervention, or died. As expected, there was no incidence of graft versus host disease in the OTL-101 group, compared with eight patients who received HSCT. Eighteen of 20 patients in the fresh formulation study stopped immunoglobin replacement therapy after two years, compared to 52% of HSCT patients. Of the seven patients treated with the cryopreserved formulation with 18 months of follow-up, five had discontinued IgRT, which is comparable to the 18-month data for patients treated with the fresh formulation.

09:19 EDT Vericel appoints Sean Flynn as general counsel - Vericel Corporation announced the appointment of Sean C. Flynn as Vice President and General Counsel. Prior to joining Vericel, Mr. Flynn held the position of Vice President and General Counsel of Verastem.

09:17 EDT Universal Insurance announces new $40M share repurchase program - Universal Insurance announced that its board has authorized a new share repurchase program under which the company may repurchase up to $40M of its outstanding shares of common stock through December 31, 2021. This new authorization follows the existing $40M share repurchase program that is expected to be completed in Q4.

09:15 EDT UPS announces UPS Simple Rate - UPS announced UPS Simple Rate, a predictable flat rate shipping option designed to help small and medium-sized businesses streamline and simplify their outbound processes. UPS Simple Rate enables SMBs to ship by UPS 2nd Day Air, UPS 3 Day Select and UPS Ground services to anywhere in the U.S. for a flat rate. It offers larger size options than what is in the marketplace today and customers do not need to enter package weight and dimensions or look up shipping zones when using UPS Simple Rate. SMBs can accurately predict their shipping costs and bill their customers without incurring unexpected fees.

09:12 EDT Kroger, TrueCar partner for Auto Buying Program - The Kroger Co. (KR) is partnering with TrueCar (TRUE) to power its new Auto Buying Program. The new Kroger Auto Buying Program powered by TrueCar provides comprehensive price context as well as upfront guaranteed savings off the manufacturer's suggested retail price on new vehicles, and discounts on used vehicles. Kroger customers will have access to more than 16,500 TrueCar Certified Dealers. They will be able to see what others in their area paid for the new car they want based on recent vehicle transactions, and will be able to access machine-learning powered price ratings on used vehicle listings. These data and tools will empower Kroger customers to assess price competitiveness on their next vehicle purchase. This program will be open to Kroger customers who shop at stores within Kroger, Dillons, King Soopers, Fred Meyers, QFC - Quality Food Centers, Ralphs and Smith's. As an additional benefit, customers who purchase a vehicle through the Kroger Auto Buying Program will be rewarded with a free Fuel VIP membership. This will allow shoppers to earn 1 extra fuel point for nearly every 1 dollar spent, doubling the money that they can save at the pump.

09:08 EDT Sentinel Energy announces cancellation of stockholder meeting - Sentinel Energy Services announced that its board of directors has determined to cancel its special meeting of stockholders that was scheduled for November 6, 2019 and to redeem all of its outstanding shares of Class A common stock, effective as of the close of business on November 7, 2019, because the Company will not consummate an initial business combination within the time period required by its certificate of incorporation. Pursuant to the Charter, if the Company does not consummate an initial business combination by November 7, 2019, the Company will: cease all operations except for the purpose of winding up, as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to the Company to pay its taxes , divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders subject to applicable law, and as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining stockholders and the board of directors, dissolve and liquidate, subject in each case to the Company's obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Net of taxes and dissolution expenses, the per-share redemption price for the public shares is expected to be approximately $10.29. The Company anticipates that the public shares will cease trading as of the open of business on November 8, 2019 in order to allow time for the settlement of trades. As of the close of business on November 7, 2019, the public shares will be deemed cancelled and will represent only the right to receive the Redemption Amount.

09:06 EDT iFresh announces termination of share exchange agreement - iFresh announced that its board of directors approved the termination of a Share Exchange Agreement with Xiaotai International Investment due to an ongoing investigation of Xiaotai on illegal fundraising from the public by the Hangzhou Police Department, Binjiang Branch. iFresh entered into the Exchange Agreement with Xiaotai on June 7, 2019. On November 5, 2019, iFresh issued a written notice to Xiaotai International and Xiaotai Shareholders to terminate the Exchange Agreement, effective immediately. As a result of the termination of the Exchange Agreement, iFresh management will begin exploring other strategic alternatives.

09:04 EDT Telus completes acquisition of ADT Security Services Canada - TELUS (TU) announced that it has completed the acquisition of ADT Security Services Canada (ADT). ADT Canada is one of Canada's leading providers of security and automation solutions serving residential and business customers, with more than 500,000 customers and over 1,000 team members across the country. TELUS SmartHome Security provides customers with peace of mind with 24/7 real-time monitoring for fires, floods, carbon monoxide leaks and break-ins, and the ability to easily manage their home directly from the TELUS SmartHome Security app. Now that the transaction has closed, TELUS and ADT Canada will work together over the coming months to integrate the businesses. During this transition period, ADT Canada customers will continue to receive and access services from ADT Canada as they always have. In the near future, ADT Canada customers will receive information from TELUS about new opportunities to save on their security services, including valuable offers, in addition to details regarding potential upgrades and innovative new features.

09:03 EDT 3D Systems says NextDent Denture 3D+ receives FDA 510(k) clearance - 3D Systems announced that its new biocompatible denture material, NextDent Denture 3D+, has received 510(k) clearance from the U.S. FDA. The combination of this new dental 3D printing material, NextDent 5100 dental 3D printer, and industry-leading intra-oral scanning and dental software solutions yields an end-to-end digital dentistry solution. As a result, customers can expect more precise, predictable results than through analog techniques - enabling more efficient, cost-effective creation of dentures for patients.

09:01 EDT Casella Waste announces remarketing of $25M of revenue bonds - Casella Waste Systems announced that it has commenced the remarketing of the $25.0 million aggregate principal amount of New York State Environmental Facilities Corporation Solid Waste Disposal Revenue Bonds Series 2014 that were issued on December 18, 2014. The Bonds have a final maturity of December 1, 2044. Pursuant to the indenture under which the Bonds were offered , the interest rate period under which the Bonds were previously issued is expiring on December 2, 2019, and accordingly, Casella expects that the Bonds will be remarketed at a new interest rate for a new interest rate period commencing on December 2, 2019. The Bonds have been guaranteed by substantially all of Casella's subsidiaries, as required pursuant to the terms of the loan agreement pursuant to which the Issuer loaned the proceeds of the Bonds to Casella. The Bonds are not a general obligation of the Issuer and do not constitute an indebtedness of or a charge against the general credit of the Issuer. The Bonds are not a debt of the State of New York and are payable solely from amounts received from Casella under the terms of the Indenture. Casella intends to issue a notice of mandatory tender for the Bonds with respect to the expiring interest rate period on or about November 8, 2019. The remarketing is expected to become effective on December 2, 2019.

08:58 EDT ADT Inc. completes sale of Canadian operations to Telus - ADT Inc. (ADT) announced that it has completed the sale of ADT Security Services Canada to TELUS Corporation (TU). The transaction comprises all of ADT Canada's operations and assets. As previously announced by the Company, a one-time special dividend of $0.70 per share remains planned. The Company expects to provide an update on the Special Dividend with its third quarter 2019 earnings release on November 12, 2019. The Special Dividend was conditioned upon the closing of the ADT Canada sale transaction, which is now completed, and remains subject to further corporate action.

08:54 EDT FuelCell announces $200M strategic corporate loan facility with Orion Energy - FuelCell Energy (FCEL) announced a new, 8-year $200 million strategic corporate loan facility with Orion Energy Partners (OESX). The Company is planning to leverage the initial October/November 2019 draws totaling $80 million to primarily support execution of certain projects within the Company's $2 billion project backlog. The balance of the Facility, or $120 million, will be available over the first 18 months to invest in strategic growth, providing working capital as needed. Specifically, $80 million of the Facility will be deployed toward: Current construction and engineering costs associated with inflight projects, specifically Tulare BioMAT, Bolthouse Farms and the CMEEC U.S. Navy Base fuel cell plant; Future growth, including commencing the construction of the first of three FuelCell projects with LIPA; Increasing FuelCell Energy's unrestricted cash balance through the monetization of the Company's project portfolio and repayment of all short-term outstanding construction loan facilities; Funding outstanding dividends for Series B Preferred shareholders. The second tranche and remaining $120 million in financing is subject to the conditions contained in the agreement. In connection with the Facility, the Company has granted Orion Energy Partners warrants to purchase up to 20 million shares of the Company's common stock. 8 million shares of these shares are valued at the October 30th, 2019 closing price, while the balance, or 12 million shares are valued at a premium to the October 30th closing price.

08:50 EDT Arena Pharmaceuticals' etrasimod shows favorable PK properties in study - Arena Pharmaceuticals presented new data evaluating the human mass balance, metabolic disposition, and pharmacokinetics of etrasimod in healthy adult male volunteers. Etrasimod is an investigational next-generation sphingosine 1-phosphate receptor modulator. The results were presented at the American Association of Pharmaceutical Scientists 2019 PHARMSCI 360 Meeting in San Antonio, Texas. "Results from this human mass balance study confirm that etrasimod is slowly and extensively metabolized via multiple metabolic pathways and demonstrate no exposure from any major metabolites. Additionally, multiple metabolic pathways for etrasimod significantly reduces the likelihood of any unwanted potential drug-drug interactions," said Preston Klassen, Executive VP and Head of Research & Development at Arena. "These highly favorable PK properties of etrasimod support the best-in-disease safety demonstrated in the Phase 2 OASIS study results. We look forward to the continued development of this potential new oral treatment option in the ongoing and planned late-stage programs in IBD, and the ongoing Phase 2 program in atopic dermatitis." Etrasimod is an investigational compound that is not approved for any use in any country.

08:47 EDT Aeglea BioTherapeutics expects capital to fund operations through 1Q21 - As of September 30, 2019, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $90.2 million. Based on Aeglea's current operating plan, management believes it has sufficient capital resources to fund anticipated operations through the first quarter of 2021.

08:41 EDT CorMedix CFO Robert Cook agrees not to renew employment agreement - CorMedix announced that the Company and CFO Robert Cook have mutually agreed not to renew his employment agreement, which expires on January 31, 2020. Mr. Cook will assist the Company in transitioning his responsibilities.

08:39 EDT Internet Gold receives notice letter from Searchlight - Internet Gold - Golden Lines announced that further to the Company's previous reports regarding the Searchlight Transaction, the Company and B Communications Ltd. received a letter from Searchlight II BZQ, L.P, indicating that pursuant to Section 8.1(d) of the Share Purchase Agreement dated as of June 24, 2019, if the Closing has not occurred by November 24, 2019, then either party has the right to deliver a notice to the other parties terminating the SPA. Searchlight further indicates that based on the advice of its counsel, if the Control Permit is not issued by the close of business today, then the Closing shall not occur prior to the End Date, due to the time period required to complete various actions between the issuance of the Control Permit and the Closing. In light of the foregoing, Searchlight informed the Company and BComm that it reserves all rights to issue a termination notice pursuant to Section 8.1(d) of the SPA on the End Date, assuming that the closing has not occurred by such date.

08:36 EDT Progenics clarifies deadline for Velan's consent solicitation - Progenics Pharmaceuticals (PGNX) issued the following statement clarifying November 17, 2019 as the true deadline for Velan Capital L.P.'s consent solicitation. The company said, "The true deadline for the Velan consent solicitation is November 17, 2019, not the November 8, 2019 "goal" arbitrarily set by Velan to try and force shareholders to vote without complete information. Velan's effort to rush to obtain consents is a clear attempt to disenfranchise shareholders. Importantly, Lantheus Holdings Inc. (LNTH) expects to file with the SEC a preliminary S-4 with detailed information about the compelling transaction with Progenics before November 17. Included in the S-4 will be valuable details regarding the benefits of the transaction as well as the process undertaken by the Board-details that are necessary for shareholders to make a fully informed decision. Progenics strongly urges shareholders to wait until they have full information regarding the Lantheus transaction before making any final decisions regarding the Velan consent solicitation. Shareholders will be able to obtain free copies of the preliminary S-4, and any amendments or supplements to the S-4 filing by accessing Lantheus' filings with the SEC through the website maintained by the SEC at https://www.sec.gov."

08:33 EDT CVS Health says expects 1,500 health hubs by end of 2021 - Says: Well-positioned for 2021 selling season... Real estate footprint remains "very productive"... For Q4, the company noted, "The first three quarters had the highest year-over-year earnings growth as we lap the addition of Aetna... Adjusted operating income for HCB expected to be lowest in Q4 due to typical seasonality of the business and spending to support January 1 readiness for Medicare business, consistent with prior years... Q4 will include higher sequential spending on our Transformation programs...Given the timing of the Aetna transaction close, Q4 2018 does not include the full impact of share dilution and interest expense from the transaction, affecting the year-over-year comparability." Comments taken from Q3 earnings conference call.

08:30 EDT Exxon Mobil, FuelCell expand agreement for carbon capture technology - ExxonMobil (XOM) and FuelCell Energy (FCEL) said they have signed a new, two-year expanded joint-development agreement to further enhance carbonate fuel cell technology for the purpose of capturing carbon dioxide from industrial facilities. The agreement, worth up to $60 million, will focus efforts on optimizing the core technology, overall process integration and large-scale deployment of carbon capture solutions. ExxonMobil is exploring options to conduct a pilot test of next-generation fuel cell carbon capture solution at one of its operating sites. FuelCell Energy's proprietary technology uses carbonate fuel cells to efficiently capture and concentrate carbon dioxide streams from large industrial sources. Combustion exhaust is directed to the fuel cell, which produces power while capturing and concentrating carbon dioxide for permanent storage. The modular design enables the technology to be deployed at a wide range of locations, which could lead to a more cost efficient path for large-scale deployment of carbon capture and sequestration.

08:26 EDT VBL Therapeutics announces new IND for Phase 2 trial of VB-111 in rGBM - VBL Therapeutics announced that an investigational new drug application has received clearance from the U.S. Food and Drug Administration. The IND is for a Phase 2 randomized, controlled, clinical trial of VB-111 in rGBM patients undergoing a second surgery. In this new study, VB-111 will be administrated either before and after the surgery or just after the surgery and will be compared to a standard of care control cohort. The IND was submitted by Patrick Wen, M.D., Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on behalf of a group of top neuro-oncology US medical centers. A prior Phase 2 study demonstrated a survival benefit for patients with rGBM primed with VB-111 monotherapy that was continued upon progression with a combination of VB-111 and bevacizumab. The primary endpoint of this new study in participants with surgically accessible rGBM is to investigate whether administration of VB-111 as a neo-adjuvant treatment prior to surgery can result in an increase in tumor infiltrating T lymphocyte within the tumor and enhance systemic tumor-specific T cell responses. Secondary endpoints will include progression free survival at 6 months and overall survival.

08:23 EDT Live Ventures to acquire Lonesome Oak Trading, terms not disclosed - Live Ventures Incorporated announced that one of its subsidiaries has entered into an agreement to acquire all of the outstanding stock of Lonesome Oak Trading Co., a leading carpet manufacturer. The acquisition is expected to close in the fourth calendar quarter of this year. Lonesome Oak, located in the Dalton, Georgia area, is a tufted textile manufacturer that sells carpet domestically and internationally. In addition, Lonesome Oak also purchases and resells hardwood flooring and luxury vinyl tile in the United States. Lonesome Oak maintains over 433,000 square feet of facility space and employs 282 full-time employees. The acquisition of Lonesome Oak is expected to increase Live Ventures' consolidated revenues by approximately 50% in its manufacturing segment to more than $130M per year.

08:21 EDT BorgWarner to supply P2 hybrid solutions for ChangAn's new transmission - BorgWarner has entered into an agreement with Chinese original equipment manufacturer ChangAn Automobile to supply its triple-clutch P2 drive module and electro-hydraulic control unit for ChangAn's new-generation hybrid transmission. BorgWarner expects to achieve mass production of its P2 modules on the new model of ChangAn in 2020. The P2 solution offers the possibility of integrating up to three clutches, including a disconnecting clutch, which allows the system to decouple from the engine for pure electric driving.

08:18 EDT Kingold Jewelry regains compliance with Nasdaq listing requirements - Kingold Jewelry has received a letter from Nasdaq indicating that Kingold has regained compliance with the $1.00 per share minimum closing bid price requirement for continued listing on the Nasdaq Stock Market, pursuant to the Listing Rules. This matter is now closed.

08:15 EDT Hoth Therapeutics initiates confirmatory study for lupus treatment - Hoth Therapeutics initiated a confirmatory study, related to their proprietary AEA-loaded Z-pods in the treatment of Cutaneous Lupus Erythematosus, a chronic autoimmune disease that affects the skin. The study is being conducted in partnership with Zylo Therapeutics to confirm that topical administration of Hoth's AEA-loaded Z-podsinhibits the development of CLE lesions in a well-established animal model of lupus. Hoth owns an exclusive license to develop Anandamide-loaded Z-pods(TM) for the treatment of CLE in North America.

08:13 EDT Dunkin' Brands to open 18 new restaurants in Houston area - Dunkin'signed store development agreements with new franchisee Manchester Enterprises to develop 18 new restaurants throughout Houston, TX. The group will also be developing ten multi-brand locations with Baskin-Robbins ice cream shops. With the first restaurant slated to open in the Summer of 2020, the franchisee is targeting markets throughout Houston, including Sugarland, Missouri City, Pearland, Friendswood, Galveston and Texas City. There are currently 160 Dunkin' restaurants located in Texas, and the company is continuing to recruit franchisees in the surrounding areas of Houston, Austin, Beaumont and Odessa, TX.

08:09 EDT ViaSat selected by EL AL Israel Airlines for fleet wide high-speed interfect - Viasat and EL AL Israel Airlines, the national air carrier of Israel, added the Boeing 777 widebody fleet to the mix of EL AL aircraft with Viasat's equipment for high-speed in-flight connectivity. EL AL plans to have all widebody aircraft equipped with Viasat's IFC solution and all narrow-body fleet equipped with Viasat's in-flight entertainment and connectivity offering. EL AL expects to have the majority of its fleet connected with the Viasat service by the end of 2020.

08:07 EDT Exxon Mobil, FuelCell expand agreement for carbon capture technology - ExxonMobil (XOM) and FuelCell Energy (FCEL) said they have signed a new, two-year expanded joint-development agreement to further enhance carbonate fuel cell technology for the purpose of capturing carbon dioxide from industrial facilities. The agreement, worth up to $60 million, will focus efforts on optimizing the core technology, overall process integration and large-scale deployment of carbon capture solutions. ExxonMobil is exploring options to conduct a pilot test of next-generation fuel cell carbon capture solution at one of its operating sites.

08:02 EDT Esperion lowers FY19 view for net increase in cash $70M-$80M from $90M-$100M - Esperion expects that current cash resources, coupled with expected milestone payments under the European commercial collaboration agreement and Oberland Capital revenue-based funding agreement, and bempedoic acid and the bempedoic acid / ezetimibe combination tablet commercial sales, will be sufficient to fund operations through profitability.

07:57 EDT Barrick Gold sees 2019 gold production 5.1M-5.6M ounces

07:52 EDT Sandy Spring Bancorp to acquire Rembert Pendleton Jackson - Sandy Spring Bancorp announced it has reached an agreement to acquire Rembert Pendleton Jackson, an investment and financial advisory firm located in Falls Church, Virginia. Founded in 1974, RPJ currently has more than $1.3B in assets under management. Upon closing the transaction, the combined AUM under Sandy Spring Bank's wealth management arms will be approximately $4.5B. The acquisition of RPJ further demonstrates Sandy Spring Bank's commitment to providing financial services to individuals, families and businesses at every stage of life and aligns with the company's strategic objective of diversifying sources of noninterest income. Sandy Spring Bank operates more than 50 locations throughout Maryland, Northern Virginia and Washington, D.C. The company offers a range of commercial and retail banking, mortgage, private banking, and trust services, as well as a comprehensive menu of insurance and wealth management services through its subsidiaries. Sandy Spring Bank has demonstrated consistent momentum through its strong financial performance and strategic growth throughout the Greater Washington region, including its recently announced acquisition of Revere Bank. With more than three decades of service to the national capital area, RPJ is a fee-only advisory firm and has been solely registered with the Securities and Exchange Commission since 1984. Collectively, the principals have more than 100 years of experience. Clients will not experience any impact or notice any changes. RPJ will continue to operate under the name, Rembert Pendleton Jackson, and Charles E. Rembert, CFP, AIF, Principal, will lead the company as President and will report to Caceres at Sandy Spring Bank. Rembert Pendleton Jackson's senior leadership and registered investment advisors will continue to serve their clients directly. The transaction is expected to be completed in the first quarter of 2020. Sandy Spring was advised on the transaction by Raymond James Silver Lane Advisors.

07:41 EDT Marinus expects cash, cash equivalents to fund requirements into 3Q20 - The company said, "At September 30, 2019, we had cash and cash equivalents of $39.9 million compared to $72.7 million at December 31, 2018. We believe that our cash, cash equivalents and investments as of September 30, 2019 will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2020."

07:37 EDT Albireo Pharma expects cash balance to be sufficient into 2021 - For the full year 2019, the company anticipates total expenses, including R&D and G&A expenses, to be in the range of $70M-$75M. Albireo continues to anticipate that its current cash balance will be sufficient to meet its operating needs into 2021.

07:34 EDT Papa John's says chief operating and growth officer Mike Nettles to depart - As a result of the reorganization, Chief Operating and Growth Officer Mike Nettles and Chief Marketing Officer Karlin Linhardt will leave the company after a short transition period to pursue other opportunities.

07:33 EDT Papa John's announces new, streamlined senior management team - Papa John's International (PZZA) announced a new, more streamlined senior management team, with additions to the team as well as promotions and expanded roles for key leaders. The updated management structure aligns with the company's new strategy and priorities. "After two months as CEO, I'm more excited than ever by the dedication, drive and resilience of Papa John's team members and franchisees. Today I'm announcing a new management structure that will be the foundation on which we build our future," said Rob Lynch, President and CEO. "As we introduce a more focused plan and strategic priorities for the company, we are realigning Papa John's senior management, promoting leaders within the company and adding proven talent." Max Wetzel, formerly VP, Consumer Brands and Chief Transformation Officer at PPG Industries (PPG), is joining the company as Chief Commercial and Marketing Officer, beginning November 18, 2019. Mr. Wetzel will oversee marketing, menu strategy, product innovation, customer experience and a new project management office. Jim Norberg, the company's SVP, Chief of Restaurant Operations, has been named COO, North America, and Jack Swaysland has been named COO, International. As a result of the reorganization, Chief Operating and Growth Officer Mike Nettles and Chief Marketing Officer Karlin Linhardt will leave the company after a short transition period to pursue other opportunities. In addition, CFO Joe Smith will be leaving the company in 2020 following the fiscal 2019 year-end, after almost 20 years at Papa John's. He will continue to serve as CFO while the company searches for a new CFO. The company's Executive Leadership Team also includes: Marvin Boakye, who has been named Chief People and Diversity Officer. Madeline Chadwick, who has been promoted to SVP, Communications and Corporate Affairs. In addition to internal and external communications, Chadwick will oversee the company's corporate social responsibility initiatives; Justin Falciola, Chief Insights and Technology Officer; Shane Hutchins, Chief Supply Chain Officer; and Caroline Oyler, Chief Legal and Risk Officer.

07:30 EDT Papa John's says CFO Joe Smith to depart in 2020

07:30 EDT Evogene subsidiary Canonic initiates cultivation of medical cannabis varieties - Evogene's wholly owned subsidiary Canonic initiated its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. Canonic achieved a milestone with the import of a genetically diverse seed collection of cannabis lines originating from different territories. These seeds were specifically selected to be the foundation of Canonic's advanced breeding program and product pipeline consisting of MetaYield - medical cannabis products with a stable increase of total plant active compounds, and Precise product line - medical cannabis with a stable increase of specific plant active compounds. The company has received the required regulatory approvals for both greenhouses and labs including Good Security Practice approval and possession license for cannabis from the Israeli Medical Cannabis Agency.

07:25 EDT BioCryst sees FY19 net operating cash use $105M-$130M - BioCryst continues to expect full year 2019 net operating cash use to be in the range of $105 to $130 million, and its operating expenses to be in the range of $120 to $145 million. The company's operating expense range excludes equity-based compensation expense due to the difficulty in reliably projecting this expense, as it is impacted by the volatility and price of the company's stock, as well as by the vesting of the company's outstanding performance-based stock options.

07:23 EDT Oncolytics announces results from Phase 1b REO 024 study published - Oncolytics announced that results from its previously announced Phase 1b REO 024 study of pelareorep in combination with pembrolizumab have been published in the peer-reviewed medical journal Clinical Cancer Research, a journal of the American Association for Cancer Research. The phase 1b study was designed to assess the safety and tolerability of the treatment combination in patients with confirmed metastatic adenocarcinoma of the pancreas who failed or did not tolerate first-line treatment. In addition to a strong safety profile, positive findings from the study included objective responses indicating anti-tumor activity, long-term stabilization of disease and promotion of an inflamed phenotype in patients' tumors. Importantly, these results supported advancing the combination regiment of pelareorep and Keytruda into phase 2 clinical development, which is currently ongoing.

07:22 EDT Taylor Morrison to acquire William Lyon Homes for $21.45/share in cash and stock - Taylor Morrison Home (TMHC) and William Lyon Homes (WLH) announced they have entered into a definitive agreement pursuant to which Taylor Morrison will acquire all of the outstanding shares of William Lyon Homes common stock for per share consideration of $2.50 in cash and 0.800 shares of Taylor Morrison common stock, implying a company value for William Lyon Homes of $21.45 per share or $2.4B including assumption of debt. The transaction consideration mix consists of approximately 90% Taylor Morrison stock and 10% cash. Based on current trading, Taylor Morrison stockholders will own approximately 77% of the combined company while William Lyon Homes stockholders will own approximately 23%. The transaction has been unanimously approved by the Boards of Directors of both Taylor Morrison and William Lyon Homes and will be submitted to the stockholders of William Lyon Homes for approval. The issuance of shares of Taylor Morrison common stock in the transaction will also be submitted to the stockholders of Taylor Morrison for approval. The transaction is expected to close late in the first quarter or early in the second quarter of 2020 and the closing is subject to the satisfaction of customary closing conditions. William H. Lyon, executive chairman and chairman of the board and holder of approximately 42 percent of the voting power of William Lyon Homes common stock, has agreed to vote all of the shares of William Lyon Homes common stock controlled by him in support of the transaction. "The strategic combination creates the nation's fifth largest homebuilder based on the last 12 months of closings, and firmly places Taylor Morrison in a Top 5 position in 16 of the combined 23 markets with an estimated 14,200 closings for the pro forma combined company," the companies stated.

07:21 EDT SAIC awarded $55M IT services contract by Orange County, CA - The County of Orange, California awarded Science Applications International a contract extension to continue to provide information technology managed services and solutions to agencies and departments within the county. As part of the contract, SAIC's services will support the county's data center, desktop, service desk, and applications. The firm-fixed-price contract has a base period of performance of 53 months and is valued at approximately $55 million. If exercised, the contract has two one-year options. Work will be primarily performed in Santa Ana, California.

07:18 EDT Cornerstone Building Brands sees Q4 adjusted EBITDA $135M-$150M

07:14 EDT Amazon announces Amazon Robotics innovation hub in MA, plans to create 200 jobs - Amazon announced plans to build a new state-of-the-art Amazon Robotics innovation hub and create 200 tech and advanced manufacturing jobs in Westborough, Massachusetts. Opening in 2021, the company plans to invest more than $40 million in the new site to allow Amazon Robotics to continue to grow its engineering, manufacturing, support and test teams in the state. The new 350,000 square feet facility, developed by Atlantic Management of Framingham, MA, will feature corporate offices, research and development labs, and manufacturing space and will be in addition to Amazon Robotics' current site in North Reading - together serving as the company's epicenter of robotics innovation. Amazon has created more than 4,000 full-time jobs in Massachusetts, and since 2011, invested more than $3 billion in the state, including infrastructure and compensation to our employees.

07:08 EDT Barrick Gold raises quarterly dividend 2% to 5c per share - Barrick Gold Corporation announced that its Board of Directors has declared a dividend for the third quarter of 2019 of $0.05 per share, a 25% increase on the previous quarter's dividend, payable on December 16, 2019 to shareholders of record at the close of business on November 29, 2019.9 Senior Executive Vice-President and Chief Financial Officer Graham Shuttleworth said Barrick's business continued to perform well and the increased dividend reflected its strong operating performance and growth in cashflows and is consistent with the Company's stated financial and operating objectives.

07:06 EDT Barrick Gold reports Q3 production of 1.3M ounces of gold

07:03 EDT BioCryst still sees FY19 net operating cash use $1.05M-$130M - Still sees 2019 operating expenses $120M-$145M.

06:52 EDT Office Depot announces review of potential holding company reorganization - Office Depot announced that its Board of Directors has approved a feasibility review of the implementation of a holding company reorganization, which is expected to be completed by the end of the first quarter of 2020. If implemented, the reorganization is anticipated to create a new holding company, The ODP Corporation, that will become the new parent company of Office Depot and will replace Office Depot as the public company trading on Nasdaq under Office Depot's current ticker symbol "ODP". If the holding company reorganization is implemented, existing shares of Office Depot, Inc. would be automatically converted on a one-for-one basis into shares of common stock of The ODP Corporation. Shareholders would not need to return stock certificates or otherwise take any action with respect to their shares of Office Depot common stock. The feasibility review will include confirmation that the anticipated holding company reorganization is intended to be a tax-free transaction for U.S. federal income tax purposes for Office Depot's shareholders. If approved, the holding company reorganization is intended to simplify the company's legal entity and tax structure, more closely align the company's operating assets to their respective operating channels within the legal entity structure, and increase its operational flexibility. If implemented, the public company reorganization is not expected to result in a change in the directors, executive officers, management or business of Office Depot, or to impact the timing of the declaration and payment of the company's regular quarterly dividends.

06:49 EDT Vislink receives $3M in new orders - Vislink announces that the company has received $3M in new orders in its live production, military-government and satcom markets. The new orders represent part of an order backlog that currently stands at approximately $13M, which represents a 42% year-over-year increase. The live production orders were received from clients operating in the broadcast, sports and entertainment sectors, primarily for wireless camera systems and related components. The military- government orders were for transmitter and receiver components for use by the US Navy and the US Army (which is above and beyond the $2.8M order previously announced in July 2019), and airborne downlink systems equipment from a law enforcement agency. The satcom equipment orders were received from international customers.

06:47 EDT Gilead presents data supporting non-inferior efficacy of Descovy for PrEP - Gilead Sciences announced 96-week results from the DISCOVER trial, a multi-year global Phase 3 registrational clinical trial evaluating the safety and efficacy of once-daily Descovy for HIV pre-exposure prophylaxis compared with Truvada for PrEP, in men and transgender women who have sex with men and are at risk for sexually acquired HIV infection. Descovy demonstrated non-inferior efficacy to Truvada through 96 weeks and statistically significant differences over Truvada for certain key measurements of bone and renal safety assessed in the study, which were pre-specified secondary endpoints. These data are being presented at the 17th European AIDS Conference in Basel, Switzerland. "The 96-week data from the DISCOVER trial further support the comparable efficacy of Descovy and Truvada for PrEP and offer new insights into the improved renal and bone safety profile of Descovy as measured by key bone and renal markers," said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. "As more at-risk people use PrEP for longer periods of time, the data affirm the value of Descovy for PrEP as a new HIV prevention option." In the DISCOVER trial, 5,387 study participants were randomized in a 1:1 ratio to receive either Descovy or Truvada once-daily. The primary endpoint was the incidence rate of HIV infection when 100 percent of participants completed 48 weeks, and at least 50 percent of participants completed 96 weeks. As a secondary endpoint analysis, the incidence rate ratio of Descovy to Truvada was evaluated when 100 percent of participants completed 96 weeks. Among the 2,670 participants who received Descovy over 96 weeks, eight acquired HIV. Among the 2,665 participants who received Truvada for the duration of the study, 15 acquired HIV. These results confirm the continued non-inferiority of Descovy versus Truvada. After the primary analysis, there was one new HIV infection in the Descovy arm in a study participant with significantly reduced adherence for several months.

06:41 EDT CVS Health CEO: All core businesses performed in line with or above expectations - CVS oresident and CEO Larry Merlo stated, "Our third quarter results build on the positive momentum we have seen across the company since the beginning of the year. All of our core businesses performed in line with or above expectations, reflecting strong operational execution. As a result, we delivered strong growth and generated robust operating cash flow, which enabled us to continue to delever while returning capital to our shareholders." Merlo continued, "Based on strong year-to-date performance, we are raising and narrowing our full-year 2019 Adjusted EPS guidance range to $6.97 to $7.05. As we approach the first anniversary of the Aetna acquisition, we are increasingly confident in the strength of our broad and differentiated assets as a combined company and our ability to deliver compelling value to our customers and the communities we serve. Looking ahead, we remain focused on successful execution of our strategic priorities and integration plans to unleash the full potential of our consumer-centric health care model and create value for all stakeholders."

06:38 EDT Diversified Restaurant to be acquired by ICV Partners for ~ $130M in cash - Diversified Restaurant Holdings (SAUC), one of the largest franchisees for Buffalo Wild Wings, announced the execution of a definitive merger agreement with investment entities affiliated with ICV Partners, a leading private investment firm that supports strong lower middle market companies. Under the terms of the agreement, ICV has agreed to acquire the company in an all cash transaction valued at approximately $130M, including the assumption of outstanding indebtedness and transaction expenses. DRH's common stockholders will receive $1.05 per share in cash, representing an approximate 123% premium to the company's closing share price on November 5, and an approximately 111% premium to the 30-day volume weighted average stock price. The transaction is structured as a merger of the company with a newly-formed entity affiliated with ICV, with DRH continuing as the surviving entity of such merger. Upon closing, stockholders of DRH will receive $1.05 per share in cash. The company's merger agreement with ICV was unanimously approved by the company's Board of Directors following a previously announced review of strategic alternatives undertaken by the company. The closing of the transaction is subject to stockholder approval, the consent of BWW, and other customary closing conditions. The company and ICV expect to complete the transaction by the end of 2019 or early 2020, following the annual meeting of stockholders at which the transaction will be an item presented for stockholder approval.

06:17 EDT Aircastle to be acquired for $32 per share in cash - Aircastle announced that it has entered into a definitive agreement to be acquired by a newly-formed entity controlled by affiliates of Marubeni and Mizuho Leasing. Under the terms of the merger agreement, Aircastle shareholders will receive $32.00 in cash for each common share of Aircastle, representing a total valuation of approximately $2.4B, or approximately $7.4B including debt obligations to be assumed or refinanced net of cash. "After a review of strategic alternatives by our board, we are pleased to reach this agreement with Marubeni and Mizuho Leasing, which delivers tremendous value and immediate liquidity to our shareholders," said Peter Ueberroth, Chairman of the Aircastle board. The cash consideration of $32.00 per share represents a 34% premium over Aircastle's closing stock price on October 23, the last trading day prior to Aircastle's public announcement that Aircastle was evaluating strategic alternatives, and a 41% premium over the volume weighted average share price during the 20 trading days ended October 23. The transaction is subject to customary closing conditions, including approval by Aircastle's shareholders and receipt of certain regulatory approvals, and is expected to close in the first half of 2020. Marubeni has agreed to vote the common shares of Aircastle that Marubeni and its affiliates beneficially own in favor of the transaction. Given the pending transaction, Aircastle will not host a third quarter earnings call and will not release its third quarter financial results for the period ended September 30, 2019 until Aircastle files its third quarter Form 10-Q.

06:14 EDT Lexington Realty increases quarterly dividend 2.4% to 10.5c per share - Lexington Realty declared a regular quarterly common share/unit dividend/distribution for the quarter ending December 31, 2019 of 10.5c per common share/unit payable on January 15, 2020 to common shareholders/unitholders of record as of December 31, 2019. This represents an increase of 2.4% from the previous quarterly per common share/unit dividend/distribution.

06:12 EDT Perion Network sees FY19 adjusted EBITDA $25M-$27M range - Says now expects to reach or exceed the top end of the range.

06:10 EDT Venator retained Citi as advisor to explore potential sale of pigments unit - Simon Turner, President and CEO of Venator, commented: "Following a comprehensive review of our color pigments business, we identified meaningful self-help measures that should improve the annual EBITDA of the business by approximately $10 million, for a similar amount of investment. We also have received inquiries from third parties expressing interest in purchasing this business. In order to maximize value for our shareholders, we have retained Citi as a financial advisor to assist us in exploring a potential sale."

06:06 EDT Covia sees FY19 CapEx $85M-$95M

06:02 EDT AstraZeneca backs $1B China biotech fund for smaller ventures - AstraZeneca announced three large-scale initiatives to build on the company's long-standing commitment to China and advance global research and development for innovative new medicines. Based in the Jing'an district of central Shanghai, the Global R&D Centre will carry out R&D for potential new innovative medicines and more than double AstraZeneca's Shanghai R&D headcount to around 1,000. Its primary focus will be on diseases that are prevalent in China, home to around a quarter of world's disease burden, as well as other parts of Asia. A new AI Innovation Centre, also in Shanghai, will be established to capitalise on the latest digital technology in R&D, manufacturing, operations and commercialisation in order to accelerate the delivery of medicines to patients in China and globally. A dedicated group within the centre will focus on collaboration with technology companies and local start-ups to develop innovative solutions for patients. The agreement with CICC to jointly create the Healthcare Industrial Fund combines the bank's strong investment and capital management experience with AstraZeneca's expertise in healthcare and will seek to drive innovation in China's healthcare system. The fund's target size is $1B and, as a first step, it will support domestic companies and partners including those based in the Wuxi International Life Science Innovation Campus, as well as international companies looking to establish a presence in China. The fund will be the first and largest-scale healthcare industrial fund established by AstraZeneca. Reference Link

05:21 EDT Cedar Fair raises quarterly dividend to 93.5c per share - Cedar Fair also announced the declaration of a quarterly cash distribution of 93.5c per LP unit, to be paid on December 17, to unitholders of record on December 4.